Vertex Pharmaceuticals Inc / Ma

Vertex Pharmaceuticals Inc / Ma

VRTX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +12.6% in FY2025

Reshma Kewalramani is the CEO of Vertex Pharmaceuticals Inc / Ma and was paid $21.1M in FY2025 (Dec), down 2%.

Pay$100 in the stock at the end of FY20 → $192
CEO pay is from each Vertex Pharmaceuticals Inc / Ma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Reshma KewalramaniFY2025
  2. 2Stuart A. ArbuckleFY2025
  3. 3Charles F. Wagner, Jr.FY2025
  4. 4Nia TatsisFY2025
  5. 5Amit SachdevFY2025
  6. 6Carmen BozicFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Vertex Pharmaceuticals Inc / Ma paid its 6 named executives $59.8M in total in FY2025 (Dec). CEO Reshma Kewalramani was paid $21.1M of that.

Name
Reshma KewalramaniCEO and President
Stuart A. ArbuckleEVP & Chief Operating Officer
Charles F. Wagner, Jr.EVP & Chief Financial Officer
Nia TatsisEVP & Chief Regulatory and Quality OfficerNot disclosed
Amit SachdevEVP & Chief Patient and External Affairs OfficerNot disclosedNot disclosed
Carmen BozicEVP & Chief Medical OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers12

See all

The FY2024 (Dec) proxy of Vertex Pharmaceuticals Inc / Ma names 12 peer companies for pay. Among Vertex Pharmaceuticals Inc / Ma and these peers, CEO pay was 5th highest of 9 and total shareholder return was 5th highest of 9.

5th highest of 9in Vertex Pharmaceuticals Inc / Ma and its pay peers, FY2024 (Dec) by CEO pay:

$6.8M$29.2M

5th highest of 9in Vertex Pharmaceuticals Inc / Ma and its pay peers, FY2024 (Dec) by total shareholder return:

$52$627

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board8

See all
  • Jeffrey LeidenChair · 16 yr on the boardNot independent—Paid as an executive
  • Alan GarberDirector · 8 yr on the boardIndependentCorporate Governance and Nominating, Science and Technology—Paid as an executive
  • Lloyd CarneyDirector · 6 yr on the boardIndependentAudit and Finance (Chair), Corporate Governance and Nominating (Chair)—Paid as an executive
  • Diana L. McKenzieDirector · 5 yr on the boardIndependentAudit and Finance, Management Development and Compensation—Paid as an executive
  • Michel LagardeDirector · 2 yr on the boardIndependentAudit and Finance—Paid as an executive
  • Jennifer SchneiderDirector · 1 yr on the boardIndependentManagement Development and Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

No new filings about this company in the feed.

Filings23

See all
Current report8-KOct 20, 2026—
Current report8-KSep 1, 2026—
Current report8-KMay 13, 2026—
Current report8-KApr 29, 2026—
Proxy statementDEF 14AApr 2, 2026FY2025
Annual report10-KFeb 13, 2026FY2025